세계의 포진성 피부염 시장 예측(-2030년) : 치료, 투여 경로, 유통 채널 및 지역별 분석

According to Stratistics MRC, the Global Dermatitis Herpetiformis Market is growing at a CAGR of 9.2% during the forecast period. Dermatitis Herpetiformis is a chronic autoimmune illness marked by strong itching and burning sensations, resulting in a skin rash. People with celiac disease, a gluten-sensitive enteropathy or anomaly in gluten digestion, frequently have it. Epidemiologically speaking, it is a rare disease that primarily affects young adults. The final course of treatment entails a strict gluten-free diet, with which skin improvement is anticipated in a few months, though it might take years for the gluten-free diet to be the only course of treatment.

According to the DermNet NZ organisation, Patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females.

Market Dynamics:

Driver:

Increasing incidence of dermatitis herpetiformis

Patients with dermatitis herpetiformis have severe itching. It is a long-term autoimmune condition that results in intense itchiness, burning, and skin rashes. People with celiac disease, gluten-sensitive enteropathy, or issues with gluten digestion are more likely to experience it. It is a rare disease that mostly affects young adults, according to epidemiology. Again, due to increasing investments in finding treatments for dermatitis herpetiformis, the market is expected to grow rapidly.

Restraint:

Complications associated with treatment

Patients could, however, experience dental issues. Additionally, it's possible that dermatitis herpetiformis will be mistaken for scabies. Due to therapeutic medications, the patient also suffers anemia, osteoporosis, Type 1 diabetes, and thyroid issues. Although some of the problems are uncommon, there is a potential that they could result in neurological conditions including ataxia and neuropathy. The negative consequences of dapsone use, such as a drop in hemoglobin, which can cause sore throats, fainting spells, dizziness, and even liver problems in some people, are another reason that can limit market expansion.

Opportunity:

Advantageous reimbursement procedures

The increasing incidence of dermatitis and the favorable reimbursement policies in developing nations are also anticipated to contribute to the market growth rate. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the global market.

Threat:

High cost

The market is severely constrained by the treatment's high cost. Patients may be burdened by the costs of long-term care, which may include prescription drugs and wellness visits, and this may prevent them from accessing the best possible treatment options. Furthermore, it is projected that the industry will be significantly impacted by the advent of generic treatment options and strict regulatory constraints.

COVID-19 Impact:

The corona virus crisis and subsequent lockdown in several nations worldwide have financially impacted major urea cycle disorders treatment firms. Moreover, the private healthcare sector is one of the areas that the pandemic has damaged the most. The pandemic has had a detrimental impact on the worldwide market regarding research and development, production, and pharmaceutical supply. In addition, due to government lockdowns in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations worldwide.

The topical segment is expected to be the largest during the forecast period

The topical segment is expected to be the largest during the forecast period. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behaviour maintenance, which is expected to drive segment growth in the market.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

The retail pharmacies segment is expected to have the highest CAGR during the forecast period. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, owing to increased inherited and genetic mutation related disorders. This is primarily attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and advancement in atopic dermatitis industry. The increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the low awareness among patients. This is attributed to strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure. With the rise in R&D projects in countries, developing medical infrastructure, rise in acceptance of technologically advanced surgical procedures and rising government initiatives, the market is expected to witness growth over forecast period.

Key players in the market:

Some of the key players in Dermatitis Herpetiformis market include: Allergan, 3B scientific, Acros Organics, Aidance Scientific, AlliChem, Aidance Scientific, Canyon Bakehouse, GlaxoSmithKline Pharmaceuticals Ltd., HBC Chem, Ivy Fine chemicals, Nostrum Laboratories Inc., Pfizer Inc., Shingles Skincare, AbbVie Inc. and Waterstone Technology.

Key Developments:

In May 2023, AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within Allergan's Juvederm dermal filler collection.

In May 2022, Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis. The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan.

In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.

Treatments Covered:

• Therapeutics
• Dietary
• Other Treatments

Route of Administrations Covered:

• Topical
• Oral

Distribution channels Covered:

• Retail stores
• E-Commerce
• Pharmacies
• Other Distribution channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Dermatitis Herpetiformis Market, By Treatment

• 5.1 Introduction
• 5.2 Therapeutics
  • 5.2.1 Topical Corticosteroids
  • 5.2.2 Sulfa Drugs
  • 5.2.3 Dapsone
• 5.3 Dietary
  • 5.3.1 Ready-to-eat Meals
  • 5.3.2 Bakery Products
  • 5.3.3 Pasta
• 5.4 Other Treatments

6 Global Dermatitis Herpetiformis Market, By Route of Administration

• 6.1 Introduction
• 6.2 Topical
• 6.3 Oral

7 Global Dermatitis Herpetiformis Market, By Distribution channel

• 7.1 Introduction
• 7.2 Retail stores
• 7.3 E-Commerce
• 7.4 Pharmacies
• 7.5 Other Distribution channels

8 Global Dermatitis Herpetiformis Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Allergan
• 10.2 3B scientific
• 10.3 Acros Organics
• 10.4 Aidance Scientific
• 10.5 AlliChem
• 10.6 Aidance Scientific
• 10.7 Canyon Bakehouse
• 10.8 GlaxoSmithKline Pharmaceuticals Ltd.
• 10.9 HBC Chem
• 10.10 Ivy Fine chemicals
• 10.11 Nostrum Laboratories Inc.
• 10.12 Pfizer Inc.
• 10.13 Shingles Skincare
• 10.14 AbbVie Inc.
• 10.15 Waterstone Technology